AnalystsJames CondulisJames Condulis's Stock Forecasts
AnalystsJames Condulis
Sectors:
Industries:
Analyst Ranking
Top 49%
#2573 out of 5256 analysts
Average Return
+1.39%
Win Rate
50%5 out of 10
Risk vs Reward
Poor
Good
James Condulis's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Newamsterdam Pharma Co NvNAMS | +54.85% | $21.84 | $33.82 | 2025-06-09 - 2026-04-20 | Strong Buy |
Cytokinetics IncCYTK | +34.64% | $46.82 | $63.04 | 2025-01-21 - 2026-01-21 | Strong Buy |
Cytokinetics IncCYTK | +33.29% | $49.62 | $66.14 | 2025-09-01 - 2026-04-20 | Strong Buy |
Amylyx Pharmaceuticals IncAMLX | +24.52% | $14.11 | $17.57 | 2026-03-02 - 2026-04-20 | Strong Buy |
X4 Pharmaceuticals IncXFOR | +5.28% | $3.98 | $4.19 | 2025-12-04 - 2026-04-20 | Strong Buy |
James Condulis Analyst Color
Get additional color on James Condulis's coverage of popular stocks
James Condulis's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tectonic Therapeutic IncTECX | 1 | Strong Buy | $75.00 | +160.78% | Initiates Coverage On | 8 days ago |
Amylyx Pharmaceuticals IncAMLX | 1 | Strong Buy | $21.00 | +19.52% | Initiates Coverage On | 2 months ago |
Aardvark Therapeutics IncAARD | 2 | Hold | $6.00 | +6.19% | Downgrades | 2 months ago |
Newamsterdam Pharma Co NvNAMS | 2 | Strong Buy | $50.00 | +47.84% | Maintains | 4 months ago |
X4 Pharmaceuticals IncXFOR | 1 | Strong Buy | $10.00 | +138.66% | Maintains | 5 months ago |
Cytokinetics IncCYTK | 2 | Strong Buy | $96.00 | +45.15% | Maintains | 8 months ago |
Soleno Therapeutics IncSLNO | 2 | Strong Buy | $108.00 | N/A | Maintains | a year ago |
Edgewise Therapeutics IncEWTX | 1 | Hold | $30.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.